bit.bio has successfully defended its European patent for the groundbreaking opti-ox™ technology, which facilitates the precise programming of pluripotent stem cells (PSCs), including induced pluripotent stem cells (iPSCs), into any human cell type. The European Patent Office (EPO) upheld bit.bio’s…
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative treatments for seizure disorders, announced the addition of a new patent to its intellectual property portfolio. The United States Patent and Trademark Office (USPTO) has granted a patent for…
GSK plc (LSE/NYSE: GSK) has announced new findings from the AReSVi-006 Phase III trial, which assessed the effectiveness of a single dose of Arexvy, a recombinant adjuvanted vaccine for respiratory syncytial virus (RSV), against lower respiratory tract disease (LRTD) in…
Pfizer Inc. (NYSE: PFE) has announced encouraging topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced plans to present new research at IDWeek 2024 in Los Angeles, CA, from October 16-19. The company will showcase the latest findings on its expanding vaccines and…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced that argenx has identified four new targets under their global collaboration and license agreement. This agreement grants argenx exclusive access to Halozyme’s ENHANZE® drug delivery technology, which utilizes the proprietary recombinant human hyaluronidase…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) has announced the conclusion of a sales partnership agreement with Nxera Pharma Japan Co., Ltd. (hereafter “Nxera Pharma Japan”), a subsidiary of Nxera Pharma Co., Ltd.…
Gilead Sciences, Inc. (Nasdaq: GILD) has announced the signing of non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to produce and distribute generic lenacapavir in 120 high-incidence, resource-limited countries, primarily targeting low- and lower-middle-income regions. These agreements precede any…
PharmaJet®, a leader in enhancing the efficacy of injectable treatments through innovative technology, has announced the appointment of Wouter Latour, M.D., as its new Chief Executive Officer (CEO). In addition to his new role, Dr. Latour will also serve on…
Forge Biologics, a key player in Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, has announced the launch of its FUEL™ manufacturing platform. This innovative platform aims to provide developers of adeno-associated virus (AAV) gene therapies with a…
SunLink Health Systems, Inc. (NYSE American: SSY) today reported a loss from continuing operations of $652,000 (or $0.09 per diluted share) for the fourth fiscal quarter ended June 30, 2024, an improvement from the $1,021,000 loss (or $0.15 per diluted…
Odyssey Therapeutics, Inc., a biotechnology firm at the forefront of developing next-generation precision immunomodulators for inflammatory conditions, has announced the establishment of its Scientific Advisory Board (SAB). This board features distinguished experts in immunology and therapeutic development. Stephen Blacklow, M.D.,…
